Other Clinical Trial - Safety, Efficacy, & Tolerability of BOS172738 in

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03328494` - Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies	Phase 1

NCT number	NCT03780517
Study type	Interventional
Source	Boston Pharmaceuticals
Contact
Status	Completed
Phase	Phase 1
Start date	December 12, 2018
Completion date	September 26, 2023

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms